Terms: = Thyroid cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
3 results:
1. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on clinical Behavior of Medullary thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract] [Full Text] [Related]
2. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.
Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D
Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732
[TBL] [Abstract] [Full Text] [Related]
3. The status of cdkn2a alpha (p16ink4a) and beta (p14arf) transcripts in thyroid tumour progression.
Ferru A; Fromont G; Gibelin H; Guilhot J; Savagner F; Tourani JM; Kraimps JL; Larsen CJ; Karayan-Tapon L
Br J Cancer; 2006 Dec; 95(12):1670-7. PubMed ID: 17117177
[TBL] [Abstract] [Full Text] [Related]
